PharmaNet/i3
, inVentiv Health’s clinical segment and a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it is offering a mobile application in the CRO industry for bioanalytical assays. The application will provide clients the ability to search the Company’s more than 1000 bioanalytical assays from an iPhone®, iPad®, or Android™ Smartphone.
“Bioanalytical assays are used to quantitate drugs and their metabolites in a variety of matrices and are critical to the testing of new drug candidates and clinical trials,” said Farah Ahmad, Executive Director, Business Development.
“In addition to the scientific strength of our bioanalytical team and our technology platforms, this application will afford the ease of use that ourclients are seeking; it provides instant access to information from anywhere.” added Ms. Ahmad.
To access the application:
· iPad®, iPhone®:
http://itunes.apple.com/app/pharmanet-i3-bioanalytical/id577099615?mt=8
· Android™:
https://play.google.com/store/apps/details?id=com.pharmanet.Pharmanet
iPad® and iPhone® are registered trademarks of Apple Inc. Android™ is a trademark of GoogleInc.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.